Multiple Myeloma   

The OS benefit with Zometa was seen only in patients with myeloma bone disease achieving less than or equal to a partial response. SRE risk reduction ...

For many clinical trials, a screening bone marrow biopsy is necessary to get a new baseline. Do you do the same in real-world practice?

Previous questions have focused on the newly diagnosed setting and choice of bisphosphonate versus denosumab. IMWG guidelines do recommend resuming zo...

Do you only offer it for patients with a documented IgG < 400? Do you check the IgG at all, or are you doing primary prophylaxis?

For example - minimum number of months of therapy, driving distance to clinic, at least a CR with or without MRD negativity?

Please assume that IVIG is fine (as it is for many Jehovah's Witness patients, since IgG is often not considered a blood product per se).

Specifically, do you offer closer follow-up for certain patients after local radiation?

Would you do a 24-hour urine and echocardiogram in all of these patients? Cardiac biomarkers, PT/PTT, or any other such blood tests?

Specifically, in the setting of patients that have had a PR or VGPR and are not actively progressing. 

This question seems quite specific but happens quite often. Multi-drug chemotherapy runs the risk of profound cytopenias and infections, while bispeci...

Modified HyperCVAD? V(R)D-PACE? DCEP? Are there any data to favor one over the other?

Would you prefer CAR-T or bi-specific or neither? If CAR-T, how do you approach lymphodepletion? 

i.e., 60+% bone marrow plasmacytosis, light chain ratio >100, and/or >1 MRI lesion

In addition to reversing hypercalcemia, initiating myeloma therapy, etc.

For example, would you use a tool like the Hydrashift assay? Would this change your management?